
Please try another search
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with an increase in health span. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, a mitochondrial dysfunction for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. It has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Sven Francque | - | 2023 | Member of Scientific Advisory Board |
Vera Gorbunova | - | 2023 | Chairman of Scientific Advisory Board |
Manlio Vinciguerra | - | - | Member of Scientific Advisory Board |
Mary E. Rinella | - | 2024 | Member of Scientific Advisory Board |
Tamara Lynn Joseph | 62 | 2022 | Independent Non-Executive Chairperson of the Board |
Yassine Bendiabdallah | 40 | 2021 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review